title: PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease.
abstract: BACKGROUND
  This study was designed to evaluate the efficacy and toxicity of a 12-week alternating weekly chemotherapy regimen for advanced Hodgkin's disease. Consolidative irradiation of residual masses was used in selected cases.
  
  
  METHODS
  Eighty-three patients with newly diagnosed advanced Hodgkin's disease (bulky stage IIA, stage IIB-IVB) or with progressive disease after extended field radiotherapy for early stage disease were included in this study. The patients were treated for 12 weeks with PACE BOM comprising oral prednisolone together with intravenous doxorubicin, cyclophosphamide and etoposide alternating weekly with intravenous bleomycin, vincristine and methotrexate. Limited field adjuvant radiotherapy was also given to 21 patients with localised persistent radiological abnormalities visible on chest X-ray after chemotherapy. The study end points were overall survival, failure free survival (FFS) and toxicity, particularly with respect to reproductive function.
  
  
  RESULTS
  With a median post treatment follow up of 52 months the actuarial 5-year overall survival is 90% (confidence interval 81%-95%) and FFS is 64% (52%-74%). This treatment was well tolerated and fertility was maintained in a high proportion of young adults.
  
  
  CONCLUSIONS
  The brief duration PACE BOM regimen with or without radiotherapy appears to be comparable in efficacy to other doxorubicin containing regimens, with a favourable toxicity profile. Randomised clinical trials are now needed to evaluate the role of this and comparable initial treatment approaches to advanced Hodgkin's disease.
authors.affiliation: CRC Wessex Medical Oncology Unit, Royal South Hants Hospital, Southampton, UK.
authors.forename: P D
authors.initials: PD
authors.lastname: Simmonds
authors.forename: G M
authors.initials: GM
authors.lastname: Mead
authors.forename: J W
authors.initials: JW
authors.lastname: Sweetenham
authors.forename: A
authors.initials: A
authors.lastname: O'Callaghan
authors.forename: P
authors.initials: P
authors.lastname: Smartt
authors.forename: J
authors.initials: J
authors.lastname: Kerr
authors.forename: C R
authors.initials: CR
authors.lastname: Hamilton
authors.forename: P F
authors.initials: PF
authors.lastname: Golding
authors.forename: A E
authors.initials: AE
authors.lastname: Milne
authors.forename: J M
authors.initials: JM
authors.lastname: Whitehouse
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005298:Fertility / Q000187:drug effects; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage; D019233:Retreatment; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008727:Methotrexate